Test Price
2,800 AED✅ Home Collection Available
GARS1 Gene Distal Hereditary Motor Neuropathy Type 5 (dHMN5) Genetic Test in UAE | AED 2800
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Next‑Generation Sequencing with Sanger Confirmation.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Complimentary Telephonic Post-Test Guidance with a DHA-Licensed Medical Geneticist.
Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731
Test Overview & Methodology
This Next‑Generation Sequencing (NGS) test comprehensively analyses all coding exons and splice sites of the GARS1 gene to detect pathogenic variants causing Distal Hereditary Motor Neuropathy Type 5 (dHMN5). The assay combines Illumina NovaSeq™ X Plus sequencing with orthogonal Sanger confirmation of clinically significant findings, guaranteeing a diagnostic yield exceeding 98% for known mutations.
| Feature | Our dHMN5 NGS Test | Standard PCR Single‑Gene Test |
|---|---|---|
| Method | NGS (Full Gene + Sanger Confirmation) | Targeted PCR (Limited Exons) |
| Sensitivity | 99.9% (All known coding/splice variants) | ~85% (Only pre‑selected hotspots) |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Clinical Utility | Definitive diagnosis, family screening, genetic counselling | Limited to common founder mutations |
Physician Insight & Safety Protocols
“A positive GARS1 result must always be correlated with nerve conduction studies and clinical presentation. As a Consultant Medical Geneticist with over 20 years of experience, I reassure families that early molecular diagnosis opens the door to proactive multidisciplinary management and genetic counselling. This test is not a substitute for regular neurological follow‑up.” — Lina Osama Zaki Quteineh, DHA Registration ID: 9294403
Advisory
Do not discontinue any prescribed medication, including neuroprotective or antispasticity drugs, without explicit consultation with your treating physician.
Exclusion Criteria & Emergency Red Flags
- Uncontrolled acute infection or febrile illness at time of sample collection.
- Inability to provide a venous blood sample (1–4 mL in EDTA) or approved buccal swab.
- Patients under 5 years old without written parental/legal guardian consent as per UAE regulations.
- Seek immediate medical care if you experience sudden severe muscle weakness, respiratory difficulty, or loss of ambulation – these are not typical of dHMN5 progression and may indicate an acute neurological emergency.
Patient FAQ & Clinical Guidance
1. What does the GARS1 NGS test detect?
This Next‑Generation Sequencing test comprehensively screens all coding exons of the GARS1 gene to identify single nucleotide variants, small insertions/deletions, and copy number variations linked to dHMN5. It is the definitive molecular diagnostic tool for confirming distal hereditary motor neuropathy type 5 when clinical signs and electromyography suggest a length‑dependent motor axonopathy.
2. How long do results take and will insurance cover it?
Standard reporting time is 3 to 4 weeks from sample receipt; we verify direct billing eligibility with most UAE insurers via WhatsApp at +971 54 548 8731. Expedited 2‑week processing is available for an additional fee when clinically urgent, and our patient coordinators handle all pre‑approval paperwork for you.
3. What preparation is needed before the blood draw?
No fasting or special preparation is required, but a clinical history and family pedigree should be drafted during a pre‑test genetic counselling session. Continue all prescribed medications unless your neurologist advises otherwise, and inform our phlebotomist of any bleeding disorders or anticoagulant use.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Health Information Protection
This genetic test complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. All samples are processed at a DHA‑licensed facility (License #1143) under ISO 9001:2015 Certification (Cert: INT/EGQ/2509DA/3139). Personal health information is pseudonymised and stored on UAE‑based secure servers; results are shared exclusively with the ordering physician and the patient, never with third parties without explicit consent.
Clinical & Logistical Metadata
| Test Name | GARS1 Gene Distal Hereditary Motor Neuropathy Type 5 (dHMN5) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (1–4 mL in EDTA) or Buccal Swab |
| Methodology Used | Next‑Generation Sequencing (Illumina NovaSeq™ X Plus) with Sanger Confirmation |
| ICD-10-CM Code | G60.0 |
| LOINC Code | 99269-5 |
| DHA Facility License & Laboratory Address | DHA License #1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians